The rise of multidrug-resistant Mycobacterium tuberculosis has complicated therapy for tuberculosis and led us to search for a potentially active combination of drugs against these strains. The susceptibilities of 12 strains of multidrug-resistant M. tuberculosis to standard antituberculous drugs (isoniazid, rifampin, ethambutol, and pyrazinamide), clarithromycin, and its metabolite, 14-hydroxyclarithromycin, were determined by use of the BACTEC radiometric method. All strains were resistant to at least two of the antituberculous drugs. Clarithromycin and 14-hydroxyclarithromycin MICs were in the range indicating resistance at >8.0 g/ml for all strains. Combination testing by the BACTEC method was performed with various concentrations of isoniazid, rifampin, and ethambutol, and with clarithromycin/14-hydroxyclarithromycin at fixed concentrations of 2.0/0.5 g/ml, respectively. Addition of clarithromycin/14-hydroxyclarithromycin to these antituberculous drug mixtures resulted in a 4-to 32-fold reduction in MICs of isoniazid, rifampin, and ethambutol and made resistant strains susceptible. Fractional inhibitory concentrations ranged from 0.23 to 0.50 for all strains, suggesting a synergistic interaction between standard antituberculous drugs and clarithromycin/14-hydroxyclarithromycin. The ability of clarithromycin/14-hydroxyclarithromycin to enhance the activities of isoniazid, ethambutol, and rifampin in vitro suggests that this combination may be efficacious in the treatment of multidrug-resistant M. tuberculosis infections.
incubated until a growth index of 500 was obtained on the BACTEC 460 instrument. A 1/10-ml volume (approximately 10 5 organisms) was inoculated into each vial containing drug dilutions and into a drug-free control vial. An additional 1:100 dilution of the inoculum was made and added to a second drug-free control vial. Inoculated vials were incubated at 37ЊC. Growth indices on the BACTEC 460 instrument were monitored daily. When the undiluted drug-free control vial reached the maximum growth index (999) on the BACTEC 460 instrument, the MIC was determined. The MIC was defined as the minimum concentration of drug for which the growth index was below that of the 1:100-diluted drug-free control vial.
Combination testing. Combinations of isoniazid, rifampin, and ethambutol were tested to determine any synergistic or additive effects. These drugs were tested in combination at the MIC of each and at four twofold dilutions lower. Clarithromycin and 14-hydroxyclarithromycin were also tested in combination at a fixed ratio of 4:1, which is the ratio achieved in serum (25) . Finally, isoniazid, rifampin, and ethambutol were tested in combination as described above with the addition of a fixed concentration of clarithromycin/14-hydroxyclarithromycin of 2.0/0.5 g/ml. Interpretation of the data was achieved by calculating the combined fractional inhibitory concentration (FIC) as follows: FIC ϭ (MIC a combination /MIC a alone ) ϩ (MIC b combination /MIC b alone ), etc. For combination testing of antituberculous drugs with a fixed concentration of clarithromycin/ 14-hydroxyclarithromycin of 2.0/0.5 g/ml, the FIC component of the latter two drugs for each strain was calculated as follows: FIC CLA ϭ 2.0/MIC CLA alone ; FIC 14OH ϭ 0.5/MIC 14OH alone , where CLA is clarithromycin and 14OH is 14-hydroxyclarithromycin. MICs of Ͼ16 g/ml were arbitrarily considered 32 g/ml for this purpose. The FIC was interpreted as follows: FIC of Յ0.5, synergistic activity suggested; FIC of 1 to 4, indifference suggested; FIC of Ͼ4, antagonistic activity suggested.
RESULTS

MICs of individual drugs.
The MICs of the various drugs against the study strains and the interpretations of the data are shown in Table 2 . All strains were resistant to clarithromycin and 14-hydroxyclarithromycin. Of the 12 strains tested, 11 were resistant to isoniazid, 7 were resistant to rifampin, 8 were resistant to ethambutol, and 3 were resistant to pyrazinamide. Excluding clarithromycin and 14-hydroxyclarithromycin, all strains were resistant to at least two drugs, with five strains resistant to three drugs and none resistant to all four drugs.
Combination testing of clarithromycin with its metabolite. Combination testing of clarithromycin and 14-hydroxyclarithromycin in a 4:1 ratio demonstrated no enhancement of clarithromycin activity. MICs of clarithromycin when the metabolite was added were unchanged from MICs of the drug alone. The FICs for all strains tested with the combination ranged from 1.125 to 1.250 and indicated indifference (data not shown).
Combination testing of antituberculous drugs. Results of combination testing of isoniazid, rifampin, and ethambutol are shown in Table 3 . If a strain was susceptible to an antituberculous drug, that drug was not tested in combination with the others. In no case did the combination of antituberculous drugs affect the MICs of the drugs individually by more than a single twofold dilution. Thus, the FICs for all strains indicated indifference to the combinations.
Combination testing of antituberculous drugs with clarithromycin and its metabolite. Results of combination testing of isoniazid, rifampin, and ethambutol plus clarithromycin/14-hydroxyclarithromycin in a fixed concentration of 2.0/0.5 g/ml are shown in Table 4 . Again, if a strain was susceptible to an antituberculous drug, that drug was not tested in combination with the others. Upon addition of clarithromycin and its metabolite to antituberculous drugs, the MICs of the latter decreased significantly in all cases. These decreases ranged from 4-to 32-fold. Corresponding FIC indices for all strains indicated synergism for the combinations.
DISCUSSION
The resurgence of tuberculosis worldwide coupled with the increase in multidrug-resistant M. tuberculosis isolates has renewed interest in the development of new antituberculous treatment regimens. Clarithromycin is a new macrolide antibiotic which achieves good concentrations in the respiratory tract, is orally administered, and has been shown to have antimycobacterial activity (1, 3, 4, 8, 11, 23) . These facts led us to Clarithromycin and its metabolite, either alone or in combination, had very little activity against multidrug-resistant M. tuberculosis. This is in agreement with previous studies which have shown a MIC 90 of Ͼ10 g/ml for M. tuberculosis (13, 26) and only modest activity in a murine model of tuberculosis (21) .
The strains used in this study were resistant to two or more antituberculous drugs (isoniazid, rifampin, ethambutol, and pyrazinamide). When isoniazid, rifampin, and ethambutol were used in combination against resistant strains, no enhancement of activity was observed. However, when clarithromycin and 14-hydroxyclarithromycin were added to the combination, the MICs of isoniazid, rifampin, and/or ethambutol dropped precipitously (4-to 32-fold). This enhancement of activity was observed with different strains when clarithromycin and its metabolite were added to the combination of isoniazid plus rifampin plus ethambutol (five strains), rifampin plus ethambutol (one strain), isoniazid plus rifampin (one strain), and isoniazid plus ethambutol (five strains). Thus, the enhancement of activity did not seem to be dependent on the presence of any single antituberculous drug. Luna-Herrera and coworkers (22) demonstrated enhancement of rifampin activity (BACTEC method) and rifampin and isoniazid activity (macrophage model) upon addition of clarithromycin to a susceptible H 37 Rv strain of M. tuberculosis but not for multidrugresistant strains.
The explanation for this apparent synergistic interaction between clarithromycin/14-hydroxyclarithromycin and isoniazid, rifampin, and/or ethambutol, in the face of resistance to all, is unclear. The mechanism of action of clarithromycin against bacteria is inhibition of protein synthesis (25) . Whether this mechanism is the same for mycobacteria is unknown. Rastogi and Labrousse (26) have shown that clarithromycin treatment of M. avium complex infection results in the disorganization of the outer wall layer and the cytoplasmic membrane of the cell envelope. These effects were seen after the organisms were incubated with clarithromycin for 72 h; thus, it is uncertain whether they are primary or secondary. If clarithromycin affects cell wall and membrane architecture in M. tuberculosis as it apparently does in M. avium complex (26) , it is conceivable that this disruption allows isoniazid, rifampin, and/or ethambutol to gain access to the drug-resistant cell. This assumes that impermeability plays an important role in resistance to these drugs, a view held by some investigators (20, 28) . The fact that the strains in this study are resistant to clarithromycin argues against this hypothesis. However, these effects may occur to a lesser degree in resistant strains, allowing for growth but still permitting the permeation of antituberculous drugs which would normally be excluded.
Alternatively, enough minor cell wall disruption may still be caused by isoniazid and ethambutol, despite in vitro resistance, to allow for the penetration of clarithromycin into the cell when it would normally be excluded. Clarithromycin in this scenario would then be the drug which actively causes growth inhibition. Indeed, rifampin and ethambutol have been shown to enhance clarithromycin activity in M. avium (26) . This hypothesis presupposes that impermeability is the mechanism of resistance to clarithromycin in M. tuberculosis. This may not be the case, since clarithromycin apparently penetrates the cell envelope of other mycobacteria to a degree sufficient to cause inhibition (1, 3, 4, 8, 23) .
In summary, clarithromycin/14-hydroxyclarithromycin significantly enhanced the in vitro antimycobacterial activities of isoniazid, rifampin, and ethambutol against multidrug-resistant M. tuberculosis. MICs of these drugs were lowered to a level sufficient to restore susceptibility to all initially resistant strains. How this was achieved in the face of phenotypic resistance to clarithromycin is unknown. Irrespective of the mechanism by which it occurs, synergism between clarithromycin and isoniazid, rifampin, and ethambutol in multidrug-resistant M. tuberculosis is a new and potentially significant finding. It would be of interest to determine if this effect could be demonstrated in an animal model of infection. If eventually proven efficacious and relatively nontoxic in humans, addition of this drug combination to the antituberculous armamentarium, especially for multidrug-resistant strains, may be highly beneficial. With therapeutic options for multidrug-resistant strains of M. tuberculosis severely limited, the use of clarithromycin, a relatively nontoxic, oral drug with excellent bioavailability, in combination with other antituberculous drugs should be further investigated. b Fixed concentration of clarithromycin/14-hydroxyclarithromycin of 2.0/0.5 g/ml added to antituberculous drugs.
